Clinical characteristic and pathogenesis of tumor-induced acute pancreatitis: a predictive model

Linlin Zheng1, Ping Zhao2, Xiaoqian Peng1, Yunhui Zhou1, Yichen Bao1, Yuling Sun3 and Lin Zhou1*

Abstract

Background: The aim of our study was to investigate the clinical characteristics and pathogenesis of tumor-induced acute pancreatitis (AP), and to develop a reliable prediction model of the clinical features to guide the diagnosis and treatment.

Methods: Patients with AP between January 2013 and December 2021 were enrolled in the study and were subdivided into the tumor group and the non-tumor group. The tumor group was subdivided into three groups based on the primary sites. Characteristic parameters, laboratory and imaging results were compared between groups. Least absolute shrinkage and selection operator regression model, XGBoost and random forest model were used to select the predictors associated with tumor-induced AP. Logistic regression analysis was used to validate the performance of the selected predictors and a nomogram was established to provide individualized probability of a tumor origin for AP.

Results: A total amount of 8970 patients were admitted for AP during the study period, and 8637 AP patients were enrolled in the study. Of these, 100 cases (1.16%) were tumor-induced AP. The tumor group was significantly older than the non-tumor group (t = 6.050, p = 0.000). Mild AP was observed in 90 cases, moderate AP in 9 cases and severe AP in one case. Tumors respectively originated from distal bile duct (14 cases), ampulla (13 cases) and pancreas (73 cases). The median time from initial AP to tumor diagnosis was 8.57 weeks and the median number of episode was 2 in the tumor group, which significantly surpassed the non-tumor group (p = 0.000). Age, white blood cell count, percentage of neutrophils, pancreatic or bile duct dilation and recurrent attacks were selected independent predictors for tumor origin. A nomogram model based on these factors was established.

Conclusion: For patients with agnogenic AP, elderly man, recurrent attacks, pancreatic or bile duct dilatation and continuous no significant increase of inflammatory markers prompt to further screening of pancreatic biliary and ampulla.

Keywords: Tumor-induced acute pancreatitis, Characteristics, Pathogenesis, Predictor, Machine learning

Introduction

Acute pancreatitis (AP) is the most common principal gastrointestinal discharge diagnosis [1], with the year global incidence of 34/100000 [2]. The occurrence of an acute inflammatory process of the pancreatic parenchyma induced by mass of tumor has been reported [3]. As a doubling in the global annual number of pancreatic
cancer diagnosed in the past two decades [4], tumor such as pancreatic cancer is becoming an increasing problem of pancreatitis-related hospitalization. However, international consensus guidelines on the diagnosis and management of tumor-induced AP do not yet specifically exist, and the effects of clinical characteristic and pathogenesis of tumor-induced AP on prognostic evaluation still remain controversial.

Tumor is easy to be misdiagnosed at the first admission due to the similar clinical characteristics of AP caused by whichever etiology [3]. It is a challenging dilemma, and meant to increase times and length of hospitalization, lead to serious complications [5], or even shorten the survival of AP patients. Significantly, there has been a growing appreciation of tumor-induced AP in recent years. It is crucial to timely identify tumor as the cause of this entity, and initiate a tailored treatment plan. In the present study, a reliable clinical prediction model was established by three machine learning algorithms. Multiple logistic regression model was developed to verify these predictors. In this way, we seek to highlight the clinical characteristics and pathogenesis on diagnosis and treatment of tumor-induced AP.

Methods
Patients selection
The data for the prevalence of tumor-induced AP came from retrospective studies. Patients firstly diagnosed AP at the First Affiliated Hospital of Zhengzhou University between 1 January 2013 and 31 December 2021 were enrolled in this study. Clinical medical information was obtained at the admission when AP and tumor diagnosis synchronously happened from the electronic medical record management system. AP patients induced by tumor were pathologically confirmed by histological examination of surgical specimens or fine needle biopsy, which were the tumor group. In contrast, 360 cases were random sampled from those AP patients with other etiologies using R software and the sample was used as the non-tumor group. Given the different primary origins, the tumor group was subdivided into the biliary group, the pancreas group and the ampulla group. Exclusions were made for the whole individuals with: (1) incomplete electronic medical records; (2) under 14 years old; (3) pregnant woman; (4) pancreatic and ampullary surgery and (5) history of pre-existing chronic pancreatitis; exclusions for the tumor group: (1) patients with incomplete pathological diagnosis information; (2) metastatic tumor. The follow-up was calculated from the date of histological diagnosis to 31 January 2022 or death. The study was approved by Ethical Committee of the First Affiliated Hospital of Zhengzhou University (2022-KY-0134).

Diagnostic criteria
AP can be diagnosed if at least two of the following three criteria were fulfilled: (1) abdominal pain (acute onset of persistent and severe epigastric pain, often radiating to the back); (2) serum lipase (or amylase) activity at least three times the upper limit of normal; (3) or characteristic findings of AP on contrast-enhanced CT or, less often, MRI or transabdominal ultrasonography [6]. Severity of AP was classified into MAP, MSAP and SAP, based on the Revised Atlanta classification [7]. Recurrent acute pancreatitis was defined as one or more new episodes of acute pancreatitis at least 3 months after the first episode [8] and absence of morphological criteria for chronic pancreatitis [9]. The numerical rating scale (NRS) was used to assess pain. The TNM stage was evaluated according to the American Joint Commission on Cancer (8th Edition).

Pancreatic duct dilation was defined as the maximum diameter was greater than 3 mm, meanwhile, bile duct dilation was considered as the maximum diameter was greater than 7 mm [10]. Vascular invasion on CT was defined as the fat disappears between the mass and adjacent vessels, the mass wrapped around the adjacent vessel at >180° and the presence of blocked blood vessels and stenosis [11]. All imaging studies were interpreted by two experienced radiologists who were unaware of the assignments.

Statistical analysis
After filtering the data based on the exclusion criteria, percentages of tumor-induced AP among AP were annually calculated from 2013 to 2021. The etiological composition of patients with AP from 2019 to 2021 was further analyzed by horizontally comparing tumor to other etiologies.

The demographic differences of patients in tumor group were compared to those in non-tumor group. The LASSO regression model with the “lambda.1se” criterion, XGB and random forest were used for the selection of predictive variables. A 75:25 training and test split was used to train and evaluate independent predictors for tumor-induced AP. The randomized data division was developed to avoid data bias and ensure a balanced distribution in both the training and test sets. Performance of these multivariable models was evaluated with receiver-operating characteristic curves (ROC) and calibration. Multiple logistic regression analyses were used to calculate Relative Risk (RR) and corresponding 95% confidence intervals (CIs). A nomogram model was built to evaluate the probability of tumor-induced AP based on the selected predictors. Additional analyses were performed.
in individuals sorted by the different tumor locations to summarize the differences.

Quantitative variables were presented as mean ± standard deviation (SD) for normal distribution and median (P25–P75) for non-normal distribution. Categorical variables were presented as absolute numbers and percentages. t-test was used for continuously normally distributed variables of two groups, one-way ANOVA was used among three groups and SNK method was used for further pair comparison. Wilcoxon test was used to evaluate non-normally distributed quantitative variables of two groups, Kruskal–Wallis H test was used among three groups and Wilcoxon test was used for further pair comparison. Bonferroni was used to correct P. Chi-square test was performed on categorical variables. The cut-off value of the intervals from first episode of AP to tumor diagnosis was defined as the Optimal Operating Point of the ROC. The tumor specific survival curve was drawn using Kaplan–Meier method and assessed using the log-rank test. Statistical significance was set at a two-sided p-value equal to 0.05. All statistical analyses were performed by using SPSS software version 25 (IBM, USA, Version 22.0) and R software (University of Auckland, New Zealand, Version 4.1.1).

Results

Epidemiology

A total amount of 8970 patients were admitted for AP during the study period, and 8637 AP patients were enrolled in the study. The incidence of tumor-induced AP was 1.16% (100/8637), and the incidence was increasing year by year. Up to now, the annual incidence rates of tumor-induced AP from 2013 to 2021 were 0.29% (2/680), 0.14% (1/713), 0.25% (2/805), 0.23% (2/852), 0.46% (5/1090), 0.34% (4/1187), 0.81% (8/983), 3.82% (40/1046) and 2.81% (36/1281).

Among 3310 patients with AP from 2019 to 2021, miscellaneous causes included cholelithiasis (52.5%), hypertriglyceridemia (16.7%), idiopathic (12.7%), diet-related (9.5%), and infection (0.8%), alcohol (1.4%), autoimmune (0.4%), operation (1.5%), dialysis (0.1%), trauma (0.5%), congenital (0.1%), thrombosis (0.0%; 2 cases), pancreatolithiasis (0.5%), poisoning (0.2%), drugs (0.1%), tumor (2.4%), metastasis (0.2%), type 1 diabetes (0.0%; 2 cases), friction of drainage tube (0.0%; 2 cases), ileus (0.0%; 1 case), biliary hemorrhage after cholecystectomy (0.0%; 1 case) and familial adenomatous polyposis (0.0%; 2 cases).

Baseline clinical features

In total, 100 individuals in tumor group and 360 admissions in the non-tumor group were enrolled (mean age 56.67 ± 11.03 versus 56.36 ± 10.70 years, p = 0.000) (Table 1). Compared with the control group, the tumor group was less likely to have gallstone-related episodes as the past history. More individuals in the tumor group had multiple episodes of AP than those in the non-tumor group (59% vs 13.3%, p = 0.000). More frequent attacks of AP were in the tumor group than the control group (Z = 8.403, p = 0.000). It took 8.57 (4.29 20.36) weeks from the first episode of AP to tumor diagnosis. The diagnosis rates at 1, 2, 3 months after the first admission were 37%, 58% and 70%. When comparing to the non-tumor group, the length of stay in the tumor group was longer (Z = 5.275, p = 0.005) and the median cost during the hospitalization was more (Z = 5.474, p = 0.001), respectively.

In tumor group, progressively aggravated intense pain in the upper abdomen was special symptom of 88 patients. Of them, 23 (26.1%) patients had previous attacks of pancreatic pain before first admission. Obstructive jaundice was in 14 patients which may result from tumor itself. MAP was observed in 90 cases, MSAP in 9 cases and SAP in one case.

87 patients (87%) underwent computed tomography (CT), 69 patients (69%) underwent ultrasound (US), 47 patients (47%) underwent magnetic resonance cholangiopancreatography (MRCP), 9 patients (9%) underwent endoscopic ultrasonography (EUS) and 11 patients (11%) underwent positron emission tomography-computed tomography (PET-CT). The sensitivities of CT, US, MRCP, EUS and PET-CT were 97.7%(85/87), 84.1%(58/69), 95.7%(45/47), 100%(9/9) and 81.8%(9/11), which assessed the rate of the number of tumors detected by imaging modalities to the number of exact cases. The presentation under CT was diffuse or focal volume enlargement of the pancreas and diffuse, segmental and cystic expansion of the pancreatic ducts. US showed diffuse enlargement of pancreatic volume, reduced internal echo and unclear boundary. The sensitivity and specificity of pancreatic duct dilation were 68.0% and 91.3%. And the sensitivity and specificity of bile duct dilation were 63.3% and 92.5%. The sensitivity and specificity of double duct sign (DDS) which represented co-existence of pancreatic and bile duct dilation were 51.0% and 96.5%.

Baseline parameters of patients with different tumors

There were 73 cases located in pancreas, 13 cases in ampulla and 14 cases in extrahepatic bile duct. The clinical characteristics of patients with tumor in different sites were summarized in Table 2. Table 3 summarized the indexes with statistically significant differences by pairwise comparison. Pancreatic duct dilation was more likely to be seen in the pancreas group than the ampulla group. The sizes of the pancreas group were significantly larger than those of the biliary and ampulla group. Albumin in the pancreas group was higher than the biliary
## Table 1  Distribution of baseline characteristics in the tumor group and in the non-tumor group

| Variables                             | Tumor N = 100          | Non-tumor N = 360         | P     |
|---------------------------------------|------------------------|---------------------------|-------|
| Age (years)                           | 56.67 ± 11.03          | 47.03 ± 15.32             | t = 7.036 0.000 |
| Sex                                   |                        |                           |       |
| Male                                  | 65 (65.0%)             | 237 (65.8%)               | χ² = 0.024 0.877 |
| Female                                | 35 (35.0%)             | 123 (34.2%)               |       |
| Smoking                               |                        |                           |       |
| No                                    | 69 (69.0%)             | 270 (75%)                 | χ² = 1.453 0.228 |
| Yes                                   | 31 (31.0%)             | 90 (25%)                  |       |
| Alcohol consumption                   |                        |                           |       |
| No                                    | 84 (84.0%)             | 291 (80.8%)               | χ² = 0.521 0.470 |
| Yes                                   | 16 (16.0%)             | 69 (19.2%)                |       |
| Diabetes mellitus                     |                        |                           |       |
| No                                    | 88 (88.0%)             | 310 (86.1%)               | χ² = 0.311 0.577 |
| Yes                                   | 12 (12.0%)             | 50 (13.9%)                |       |
| Cholelithiasis                        |                        |                           |       |
| No                                    | 74 (74.0%)             | 231 (64.2%)               | χ² = 3.387 0.066 |
| Yes                                   | 26 (26.0%)             | 129 (35.8%)               |       |
| Recurrent attacks                     |                        |                           |       |
| No                                    | 41 (41.0%)             | 312 (86.7%)               | χ² = 91.432 0.000 |
| Yes                                   | 59 (59.0%)             | 48 (13.3%)                |       |
| Pancreatic duct dilation              |                        |                           |       |
| No                                    | 31 (31.0%)             | 316 (87.8%)               | χ² = 157.330 0.000 |
| Yes                                   | 66 (66.0%)             | 30 (8.3%)                 |       |
| Unknown                               | 3 (3.0%)               | 14 (3.9%)                 |       |
| Bile duct dilation                    |                        |                           |       |
| No                                    | 36 (36.0%)             | 320 (88.9%)               | χ² = 149.367 0.000 |
| Yes                                   | 62 (62.0%)             | 26 (7.2%)                 |       |
| Unknown                               | 2 (2.0%)               | 14 (3.9%)                 |       |
| Severity of pancreatitis              |                        |                           |       |
| Mild                                  | 90 (90.0%)             | 208 (57.8%)               | H = 35.626 0.000 |
| Moderately severe                     | 9 (9.0%)               | 134 (37.2%)               |       |
| Severe                                | 1 (1.0%)               | 18 (5.0%)                 |       |
| White blood cells (× 10^9/L)          | 6.00 (4.63 7.78)       | 10.00 (6.95 14.30)        | Z = 7.811 0.000 |
| Hemoglobin (g/L)                      | 127.00 (118.00 137.85) | 131.00 (116.00 148.00)    | Z = 2.082 0.037 |
| Hematocrit value                      | 0.39 (0.36 0.42)       | 0.40 (0.35 0.44)          | Z = 1.634 0.102 |
| Neutrophilic granulocyte percentage (%) | 67.7 (58.4 73.6)       | 81.6 (69.9 88.3)          | Z = 7.735 0.000 |
| Albumin (g/L)                         | 39.7 (36.7 42.2)       | 38.1 (33.4 41.7)          | Z = 2.749 0.006 |
| Alkaline phosphatase (U/L)            | 132 (83 298)           | 82 (64 126)               | Z = 5.755 0.000 |
| Direct bilirubin (μmol/L)             | 8.7 (4.3 9.44)         | 7.1 (4.4 16.0)            | Z = 2.634 0.008 |
| Indirect bilirubin (μmol/L)           | 7.0 (4.2 15.6)         | 7.4 (4.9 13.3)            | Z = 0.403 0.687 |
| Creatinine (μmol/L)                   | 64 (55 78)             | 64 (52 80)                | Z = 0.161 0.872 |
| Amylase (U/L)                         | 145 (73 275)           | 155 (75 475)              | Z = 1.228 0.219 |
| Lipase (U/L)                          | 303.0 (181.7 874.7)    | 201.3 (80.9 624.5)        | Z = 3.351 0.001 |
| C-reactive protein (mg/L)             | 5.39 (1.82 35.45)      | 51.10 (9.76 159.35)       | Z = 4.552 0.000 |
| Serum glucose (mmol/L)                | 5.95 (4.64 7.47)       | 6.86 (5.20 9.32)          | Z = 2.958 0.003 |
| Serum calcium (mmol/L)                | 2.29 (2.21 2.35)       | 2.18 (2.06 2.29)          | Z = 5.875 0.000 |
| Triglyceride (mmol/L)                 | 1.31 (0.84 2.11)       | 1.75 (0.94 4.40)          | Z = 2.919 0.004 |
| Time (day)                            | 19 (12 29)             | 11 (8 18)                 | Z = 5.877 0.000 |
| Cost (yuan)                           | 64,297.80 (21,911.23 108,028.30) | 23,454.58 (14,498.46 43,762.65) | Z = 6.209 0.000 |
group and CEA in the pancreas group was higher than the ampulla group (all \( p < 0.05 \)).

In the pancreas group, tumors mostly located in head and neck (56/73) while partly in body and tail (17/73). The comparisons of tumor characteristics in different parts of pancreas were shown in Table 4. According to pathological classification, there were 59 adenocarcinomas, 7 mucinous cystadenomas, 2 acinar cell carcinomas, 1 squamous cell carcinoma, 2 small cell carcinomas, 1 solid pseudopapilloma and 1 intraductal papilloma. Vascular invasion was observed in 14 cases. 5 cases synchronously violated portal vein and mesenteric vessels, 1 case synchronously violated liver and pancreas itself (body and tail) as well as 1 case synchronously violated psoas major and ilium. Single organ metastases included liver (17 cases), duodenum (3 cases), bone (1 case) and

Table 2 Clinicopathological features of tumor-induced AP in different sites

| Variables                  | Pancreas \( N = 73 \) | Ampulla \( N = 13 \) | Biliary tract \( N = 14 \) | \( \chi^2 \) | \( P \) |
|----------------------------|------------------------|-----------------------|-----------------------------|------------|-------|
| Age (year)                 | 57.15 ± 11.52          | 54.31 ± 8.71          | 56.36 ± 10.70               | \( t = 0.369 \) | 0.693 |
| Sex                        |                         |                       |                             | \( \chi^2 = 0.16 \) | 0.945 |
| Male                       | 47 (64.4%)              | 9 (69.2%)             | 9 (64.3%)                   |            |       |
| Female                     | 26 (35.6%)              | 4 (30.8%)             | 5 (35.7%)                   |            |       |
| Severity of pancreatitis   |                         |                       |                             | \( \chi^2 = 0.801 \) | 0.747 |
| Mild                       | 66 (90.4%)              | 11 (84.6%)            | 13 (92.9%)                  |            |       |
| Moderate/severe/severe     | 7 (9.6%)                | 2 (15.4%)             | 1 (7.1%)                    |            |       |
| Recurrent attacks           |                         |                       |                             | \( \chi^2 = 1.754 \) | 0.416 |
| No                         | 28 (38.4%)              | 5 (38.5%)             | 8 (57.1%)                   |            |       |
| Yes                        | 45 (61.6%)              | 8 (61.5%)             | 6 (42.9%)                   |            |       |
| Pancreatic duct dilation   |                         |                       |                             | \( \chi^2 = 10.131 \) | 0.025 |
| No                         | 16 (21.9%)              | 8 (61.5%)             | 7 (50.0%)                   |            |       |
| Yes                        | 54 (74.0%)              | 5 (38.5%)             | 7 (50.0%)                   |            |       |
| Unknown                    | 3 (4.1%)                | 0                     | 0                           |            |       |
| Bile duct dilation         |                         |                       |                             | \( \chi^2 = 2.662 \) | 0.633 |
| No                         | 25 (34.2%)              | 7 (53.8%)             | 4 (28.6%)                   |            |       |
| Yes                        | 46 (63.0%)              | 6 (46.2%)             | 10 (71.4%)                  |            |       |
| Unknown                    | 2 (2.7%)                | 0                     | 0                           |            |       |
| Diameter of tumor (cm)     | 4.0 (2.3-4.8)           | 1.8 (1.5-2.5)         | 1.7 (1.5-2.5)               | \( H = 17.602 \) | 0.000 |
| White blood cells (x 10^9/L) | 5.41 (4.52-7.54)       | 5.91 (4.98-7.15)      | 7.53 (5.67-8.03)            | \( H = 2.451 \) | 0.294 |
| Hemoglobin (g/L)           | 127.02 ± 15.06          | 123.74 ± 20.10        | 125.06 ± 14.55              | \( F = 0.264 \) | 0.768 |
| Neutrophilic granulocyte percentage (%) | 66.54 ± 11.68 | 58.25 ± 22.74 | 65.22 ± 10.04 | \( F = 1.892 \) | 0.157 |
| Hematocrit value           | 0.386 ± 0.044           | 0.370 ± 0.060         | 0.372 ± 0.047               | \( F = 1.007 \) | 0.369 |
| Amylase (U/L)              | 138.0 (77.5-234.5)      | 166.0 (72.0-949.0)    | 245.0 (48.0-528.0)          | \( H = 1.981 \) | 0.371 |
| Lipase (U/L)               | 303.00 (205.10-862.20)  | 275.35 (131.55-1434.28) | 309.15 (137.63-1165.00)    | \( H = 0.250 \) | 0.883 |
| Serum glucose (mmol/L)     | 6.03 (4.98-7.89)        | 4.64 (4.19-6.01)      | 6.20 (5.02-10.29)           | \( H = 4.873 \) | 0.087 |
| Serum calcium (mmol/L)     | 2.30 (2.24-2.35)        | 2.22 (2.13-2.44)      | 2.23 (2.09-2.32)            | \( H = 5.651 \) | 0.059 |
| Albumin (g/L)              | 40.03 ± 4.23            | 41.42 ± 8.92          | 36.05 ± 4.42                | \( F = 4.506 \) | 0.014 |
| Direct bilirubin (μmol/L)  | 8.15 (4.16-110.60)      | 6.75 (3.63-49.18)     | 26.40 (6.20-137.95)         | \( H = 2.035 \) | 0.362 |
| Indirect bilirubin (μmol/L) | 7.35 (4.38-18.70)      | 4.40 (2.80-9.20)      | 5.80 (2.85-20.20)           | \( H = 3.793 \) | 0.15 |
| CEA (ng/ml)                | 4.06 (2.11-8.50)        | 1.48 (0.68-2.39)      | 2.75 (1.14-5.37)            | \( H = 12.822 \) | 0.002 |
| CA125 (U/ml)               | 23.47 (15.45-91.22)     | 38.30 (13.18-272.19)  | 23.15 (8.93-43.65)          | \( H = 1.800 \) | 0.407 |
| CA199 (U/ml)               | 193.30 (48.12-1601.50)  | 69.83 (6.86-322.25)   | 131.00 (22.64-411.00)       | \( H = 5.258 \) | 0.072 |
| Stage                      |                         |                       |                             | \( \chi^2 = 34.034 \) | 0.000 |
| I                          | 17 (23.3%)              | 3 (23.1%)             | 1 (7.1%)                    |            |       |
| II                         | 10 (13.7%)              | 1 (7.7%)              | 6 (42.9%)                   |            |       |
| III                        | 19 (26.0%)              | 0                     | 3 (21.4%)                   |            |       |
| IV                         | 27 (37.0%)              | 3 (23.1%)             | 2 (14.3%)                   |            |       |

CEA, carcino-embryonic antigen; CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 199
common bile duct (1 case). There are 27 cases (37.0%) in stage IV, 19 cases (26.0%) in stage III, 10 cases (13.7%) in stage II (3 case stage IIB and 7 case stage IIA), 17 cases (23.3%) in stage I (14 case stage IB and 3 case stage IA).

In the ampulla group, there were 6 villous tubular adenomas and 7 adenocarcinomas. Liver metastasis was observed in 1 case and biliary duct was involved in two cases. There were 3 cases (23.1%) in stage IV, 1 case (7.7%) in stage IIB and 3 cases (23.1%) in stage IIB. In the biliary group, there were 12 adenocarcinomas, 1 high-grade neoplasia with canceration and 1 villous adenoma with canceration. Vascular invasion was observed in 2 cases. Single organ metastases included pancreas (1 case), duodenum (1 case) and liver (2 cases). And there were 2 cases (14.3%) in stage IV, 3 cases (21.4%) in stage II, 6 cases (42.9%) in stage II (3 case stage IIB and 3 case stage IIA) and 1 case (7.1%) in stage IB.

Totally, 32% cases were IV stage, 22% cases were III stage, 17% cases were II stage (7 case IIB and 10 case IIA) and 21% cases were I stage (18 case IB and 3 case IA). The differences among the three groups were statistically significant ($p=0.000$).

### Predictors for tumor-induced AP

All available features with statistical significance in Table 1 except C-reactive protein (CRP) which had many missing values, cost and time were trained by LASSO regression (Figs. 1, 2), XGB (Fig. 3) and random forest model (Fig. 4). Calibration plots and receiver operator characteristic curves were used to evaluate the model.

#### Table 3 Pairwise comparison of characteristics of different origin tumor

| Variables                  | Pancreas versus ampulla | Pancreas versus biliary tract | Ampulla versus biliary tract |
|----------------------------|-------------------------|-------------------------------|----------------------------|
|                            | $p$                     | $p$                           | $p$                        |
| Pancreatic duct dilation    | $<0.05$                 | $>0.05$                       | $>0.05$                    |
| Diameter of tumor (cm)     | $H=2.675$               | $H=3.629$                     | $H=0.053$ $1.000$          |
| Albumin (g/L)              | $F=0.871$               | $F=2.933$                     | $F=2.053$ $0.120$          |
| CEA (ng/ml)                | $H=3.355$               | $H=1.697$                     | $H=1.476$ $0.420$          |

CEA, carcino-embryonic antigen

#### Table 4 Demographics and clinical characteristics of patients with pancreatic tumor-induced AP

| Variables                  | Head and neck $N=56$ | Body and tail $N=17$ | $P$   |
|----------------------------|----------------------|----------------------|-------|
| Age (year)                 | 58.36 ± 10.79        | 53.18 ± 13.23        | $t=1.644$ $0.105$ |
| Sex                        | $\chi^2=5.205$ $0.041$ |
| Male                       | 40 (71.4%)           | 7 (41.2%)            |
| Female                     | 16 (28.6%)           | 10 (58.8%)           |
| Pancreatic duct dilation   | $\chi^2=18.423$ $0.000$ |
| No                         | 6 (10.7%)            | 10 (58.8%)           |
| Yes                        | 48 (85.7%)           | 6 (35.3%)            |
| Unknown                    | 2 (3.6%)             | 1 (5.9%)             |
| Bile duct dilation         | $\chi^2=19.570$ $0.000$ |
| No                         | 12 (21.4%)           | 13 (76.5%)           |
| Yes                        | 43 (76.8%)           | 3 (17.6%)            |
| Unknown                    | 1 (1.8%)             | 1 (5.9%)             |
| Pathological classification | $\chi^2=19.473$ $0.000$ |
| Adenocarcinoma             | 51 (91.1%)           | 8 (47.1%)            |
| Solid-pseudopapillary tumor| 0                    | 1 (5.9%)             |
| Small cell carcinoma       | 0                    | 2 (11.8%)            |
| Mucinous neoplasms         | 3 (5.4%)             | 4 (23.5%)            |
| Squamous-cell carcinoma    | 1 (1.8%)             | 0                    |
| Intraductal papilloma      | 0                    | 1 (5.9%)             |
| Acinar cell carcinoma      | 1 (1.8%)             | 1 (6.3%)             |
| Diameter of tumor (cm)     | 4.00 (2.15 4.63)     | 3.00 (2.40 5.50)     | $Z=0.333$ $0.749$ |

In the ampulla group, there were 6 villous tubular adenomas and 7 adenocarcinomas. Liver metastasis was observed in 1 case and biliary duct was involved in two cases. There were 3 cases (23.1%) in stage IV, 1 case (7.7%) in stage IIB and 3 cases (23.1%) in stage IIB. In the biliary group, there were 12 adenocarcinomas, 1 high-grade neoplasia with canceration and 1 villous adenoma with canceration. Vascular invasion was observed in 2 cases. Single organ metastases included pancreas (1 case), duodenum (1 case) and liver (2 cases). And there were 2 cases (14.3%) in stage IV, 3 cases (21.4%) in stage III, 6 cases (42.9%) in stage II (3 case stage IIB and 3 case stage IIA) and 1 case (7.1%) in stage IB. Totally, 32% cases were IV stage, 22% cases were III stage, 17% cases were II stage (7 case IIB and 10 case IIA) and 21% cases were I stage (18 case IB and 3 case IA). The differences among the three groups were statistically significant ($p=0.000$).

#### Table 4 Demographics and clinical characteristics of patients with pancreatic tumor-induced AP

| Variables                  | Head and neck $N=56$ | Body and tail $N=17$ | $P$   |
|----------------------------|----------------------|----------------------|-------|
| Age (year)                 | 58.36 ± 10.79        | 53.18 ± 13.23        | $t=1.644$ $0.105$ |
| Sex                        | $\chi^2=5.205$ $0.041$ |
| Male                       | 40 (71.4%)           | 7 (41.2%)            |
| Female                     | 16 (28.6%)           | 10 (58.8%)           |
| Pancreatic duct dilation   | $\chi^2=18.423$ $0.000$ |
| No                         | 6 (10.7%)            | 10 (58.8%)           |
| Yes                        | 48 (85.7%)           | 6 (35.3%)            |
| Unknown                    | 2 (3.6%)             | 1 (5.9%)             |
| Bile duct dilation         | $\chi^2=19.570$ $0.000$ |
| No                         | 12 (21.4%)           | 13 (76.5%)           |
| Yes                        | 43 (76.8%)           | 3 (17.6%)            |
| Unknown                    | 1 (1.8%)             | 1 (5.9%)             |
| Pathological classification | $\chi^2=19.473$ $0.000$ |
| Adenocarcinoma             | 51 (91.1%)           | 8 (47.1%)            |
| Solid-pseudopapillary tumor| 0                    | 1 (5.9%)             |
| Small cell carcinoma       | 0                    | 2 (11.8%)            |
| Mucinous neoplasms         | 3 (5.4%)             | 4 (23.5%)            |
| Squamous-cell carcinoma    | 1 (1.8%)             | 0                    |
| Intraductal papilloma      | 0                    | 1 (5.9%)             |
| Acinar cell carcinoma      | 1 (1.8%)             | 1 (6.3%)             |
| Diameter of tumor (cm)     | 4.00 (2.15 4.63)     | 3.00 (2.40 5.50)     | $Z=0.333$ $0.749$ |
Interestingly, all three methods revealed that age, recurrent attacks, pancreatic duct dilation, bile duct dilation, white blood cell count and percentage of neutrophils were predictors of tumor-induced AP. These variables, as age (1.05 [1.01 1.10], \( p = 0.013 \)), recurrent attacks (6.19 [4.04 53.29], \( p = 0.000 \)), pancreatic duct dilation (13.74 [9.11 20.35], \( p = 0.000 \)), bile duct dilation (8.99 [2.42 36.57], \( p = 0.001 \)), white blood cell count (0.81 [0.66 0.97], \( p = 0.032 \)) and percentage of neutrophils (0.96 [0.92 1.00], \( p = 0.108 \)) were calculated in logistic regression analysis and then used to develop a nomogram (Fig. 5).

**Treatment and survival analysis**

Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNA) has performed in 7 patients. 38 patients underwent CT-guided biopsy to confirm the diagnosis. 41 patients were managed with pancreaticoduodenectomy, 13 patients underwent distal pancreatectomy, 2 underwent endoscopic ultrasound and endoscopic resection, 1 underwent endoscopic resection and stent implantation, 1 underwent nasojejunal feeding tube implement under endoscopy, 2 underwent cholangiography and drainage tube placement and 1 underwent percutaneous transhepatic cholangial drainage (PTCD). 7 patients merely received chemotherapy. 14 patients received surgical procedures combined with systemic chemotherapy.

There was significantly lower 3 year survival rate for no less than 3 months from AP onset to tumor diagnosis than <3 months (\( p = 0.047 \); Fig. 6). The 1, 2, 3 and 4 year cumulative survival rates of patients with tumor-induced AP were 58.9%, 44.6%, 34.4% and 17.2%. The median overall survival was 495 days (interquartile range 190.12–799.88 days).

**Discussion**

Correctly diagnosing AP etiology is a crucial step to prescribe the most appropriate therapy and prevent recurrent attacks [12]. The distribution of etiologies of AP differs by (1) region, with gallstone and alcohol as the leading causes in the United States and a predominance of gallstones in southern Europe [13], (2) period, with increased non-gallstone-related AP incidence in the early 1990s and decreased incidence in the mid-1990s to mid-2000s [14]. It is noted that tumor as currently common etiology of AP patients in China is increasingly recognized. As the overlap in clinical and imaging features of tumor-induced AP and AP from other etiologies, controversy regarding tumor-induced AP diagnosis (including clinical symptoms, biochemical and morphologic) renders differential diagnosis challenging. For comparison against the LASSO regression, more structurally complex XGB and Random forest were used to investigate predictors of tumor-induced AP in the single center cohort. A new nomogram model that consisted of age, white blood cell count, percentage of neutrophils, pancreatic or bile duct dilation and recurrent attacks was built to create a high predictive value.

A series of events with regard to mass, ranging from pancreatic-duct obstruction, and/or stasis of pancreatic juice, appear to play a fundamental role in the
Zheng et al. BMC Gastroenterology (2022) 22:422
Page 8 of 13

The pathogenesis of tumor-induced AP. Mujica et al. also speculated these pathophysiological events may trigger a series of cascading events causing acinar cell disruption, intracellular activation of proteolytic enzymes, pancreatic parenchymal edema, and peripancreatic inflammation and even pancreatic enzymes were activated directly by tumor tissue [15]. Compared with previous studies [16, 17], this study concentrated on three anatomically adjacent locations, pancreas, the papilla Vater and distal bile duct, to assess whether the tumor location influenced the differences in pathogenesis. Pancreas was the main tumor location, especially the head and neck of pancreas, followed by distal bile duct and ampulla. Among the tumors from different sites, pancreatic tumor diameter was significantly larger than the other two groups, suggesting that bile tract and ampullary tumor may have a higher rate of misdiagnosis, and need close follow-up and comprehensive imaging monitor.

With pathology providing the most robust evidence to confirm the etiology, adenocarcinoma, adenoma and mucinous tumor has become common histological types of tumor with recurrent AP as the initial symptom. Squamous cell carcinoma [18], non-Hodgkin’s lymphoma [19] and adenomyoma [20] can also be seen. In this study, both benign and malignant tumor associated AP could induce abdominal effusion, but malignant ascites was mostly related to metastasis. Previous studies have reported that ascites with high amylase content was usually associated with benign tumors [21]. Therefore, ascites biochemical and ascbsic cytology examination are of great significance for the comprehensive diagnosis of AP.
Smoking, alcohol consumption and diabetes were shared risk factors of AP and tumor [22], however, there was no significant difference between two groups. Notably, patients with tumor-induced AP were more likely to be older, male and mild entity compared to AP patients with other etiologies. The tumor group mostly presented with intermittently progressive epigastric pain which may result in the difficulty for individual first diagnosis. Furthermore, the time from initial AP to tumor diagnosis seemed to be delayed as Omid et al. described [8] and there were more episodes compared to the non-tumor group. The factors that interfere with an early diagnosis and cause recurrent attacks include that a mild course [7], ineffective imaging screening to distinguish between inflammatory edema and tumorous mass [23] and not very valuable information associated with tumor-induced AP owing to low sensitivity. Both age and recurrent attacks were the independent predictors.

Most cases were MAP which was associated with absence of organ dysfunction [24] and local or systemic complications. The suspicion appeared strengthened when MAP was combined with lower infection index including the white blood cell count, percentage of neutrophils and serum CRP. The white blood cell count was proved to be an independent predictor in the model. Percentage of neutrophils was of importance in ensemble learning, but it was validated to be not significant in the multiple logistic regression ($p = 0.108$). The effect of percentage of neutrophils needs to be further explored.

In tumor group, lipase was significantly higher than that in the control group while amylase was not. The elevated serum lipase was also seen in pancreatic and ampullary acinar cell carcinoma [25, 26] and it was an additional tool for determinations of recurrence or treatment response as Kruger suggested [27]. Significantly elevated alkaline phosphatase and direct bilirubin have been associated with biliary obstruction in tumor group. There was a persistent increase trend in specific tumor markers, such as CEA, CA199, and CA125. The level of CEA in the pancreas group was higher than the ampulla group, which confirmed malignancies accounted for majority.

Our findings reinforce the widely held belief that precise imaging should be performed when the diagnosis is compounded and patients fail to clinically improve after 2–3 days [28, 29]. CT is widely performed for the assessment of AP severity, however, its contribution to the etiologic diagnosis should not be overlooked [30]. Cho et al. suggested that patients with idiopathic AP should complete CT within 3 months after discharge to exclude occult tumors [31]. When CT does not reassure us against occult malignancy, MRI and MRCP offer alternatives with higher sensitivity but more cost, and EUS has no false positive mass detections when compared with final histopathological diagnosis. Moreover, endoscopic retrograde cholangiopancreatography (ERCP) can diagnose intraductal lesions, relieve obstruction by placing a stent and prevent recurrence until an established diagnosis and more definitive treatment can be offered [32].
believe that abdominal appearance on imaging should be incorporated into the decision algorithm for early diagnosis of tumor-induced AP.

Radiologic features include but are not limited to focal or diffuse volume enlargement, peripancreatic fluid collections. The classical features of tumor-induced AP involve pancreatic duct dilation [23]. What’s more, coexistence of pancreatic and bile duct dilation (DDS) can improve the diagnostic specificity. Both of them were independent predictors of tumor-induced AP. In this study, pancreatic duct dilation was more likely to occur in pancreatic tumor, especially the head and neck of pancreas. No difference of bile duct dilation was identified among the three groups. DDS is more common in pancreatic head-neck tumor than body-tail tumor as mass obstructs ducts causing marked dilation of upstream

---

**Fig. 4** Development and assessment of the random forest algorithm in tumor-induced AP prediction. **A** Relationship between out-of-bag error and number of trees. In total, 139 trees are selected to establish a random forest model; **B** feature importance; **C, D** Receiver-operating characteristic curves; **E, F** calibration curves
duct [17]. DDS has long been considered ominous given its presence in cases of periampullary malignancy. Of note, dilated pancreatic or bile duct in high risk patients with clinical signs require comprehensive workup and careful evaluation of the entire gland and surrounding abdominal structures [33].

When comparing to AP from other etiologies, tumors not only prolong hospitalization of AP patients, but also increase financial burden. The initial management of tumor-induced AP is similar to the others; nevertheless, exact clinical treatment has not been found to improve the whole disease course. Inflammation can increase the difficulty of surgery and postoperative complications by aggravating tissue adhesion and edema, thus affecting surgical efficacy. Timely control of inflammation progression is critical for subsequent treatment [34]. Pancreaticoduodenectomy is the key treatment for malignant tumors in this region [9]. Endoscopic treatment is feasible for small, benign tumors [9], or patients with greater surgical risk than benefit.

Earlier recognition of tumor after the first episode of AP is associated with a less advanced cancer and increases the probability of surgery with curative intent [8]. Patients had low prevalence of distant organ
metastasis at diagnosis (26.2%) and high resection frequencies (60.7%) in this study. Although MAP was not generally associated with mortality [35], the 4-year cumulative survival rate of patients with tumor-induced AP was 17.2%. It may be related to the fact that most entities were aggressive (e.g. Stage III/IV tumors accounted for 54% of the patients) and partly preformed palliative. The survival analysis revealed that the outcomes of patients with an interval of less than 3 months between the first episode of AP and tumor diagnosis were more favorable than those of patients with an interval of more than 3 months. Based on poor prognosis of periampullary and pancreatic tumor-induced AP [36], pathogenesis contributes to determinate individualized management strategies and improve prognosis.

However, there are still some limitations to this study. First, it is a retrospective study that is unavoidable to be affected by selection bias. Second, the data, such as the stage about adenoma and high-grade neoplasia, was not included in the study. Third, since it is a single-centre study, it limits the generalization of our findings to other institutions or populations with different resources. Prospective, multicenter and larger scale researches are still needed to confirm the differences in survival outcomes which caused by the initial concerns. The present work supported the value of machine learning methods for exploring for etiology of AP. There remains significant room to develop, validate and implement machine learning based AP diagnostic tools in clinical settings.

Conclusion

More cases of tumor-induced AP than expected have been confirmed, and more standardized guidelines for investigating tumor-induced AP should be put in place. Early elaborate examination of pancreas bile and ampulla is essential for tumor-induced AP. The elderly, recurrence attacks, white blood cell count, percentage of neutrophils and pancreatic or bile ducts dilatation are pretty reliable predictors for diagnosis of tumor-induced AP, thus they should be considered in etiology exploration and the ongoing individualized management of tumor-induced AP.

Abbreviations

AP: Acute pancreatitis; MAP: Mild acute pancreatitis; MSAP: Moderately severe acute pancreatitis; SAP: Severe acute pancreatitis; LASSO: Least absolute shrinkage and selection operator; XGB: XGBoost; CT: Computed tomography; MRI: Magnetic resonance imaging; MRCP: Magnetic resonance cholangio-pancreatography; US: Transabdominal ultrasound; PET-CT: Positron emission tomography-computed tomography; ERCP: Endoscopic retrograde cholangio-pancreatography; EUS: Endoscopic ultrasonography; PTCD: Percutaneous transhepatic cholangial drainage; ROC: Receiver-operating characteristic curves; RR: Relative risk; CI: Confidence interval; DDS: Double duct sign; CRP: C-reactive protein; CEA: Carcinoembryonic antigen.

Acknowledgements

Not applicable.

Author contributions

LZ and PZ participated in the design of the study, and contributed equally in designing and writing of the manuscript. LZ and PZ shared first authorship. XP, YZ, and YB collected the data. LZ and LZ performed the analysis and interpretation of the data. YB, YS and LZ revised the manuscript. All authors reviewed and approved the final manuscript.

Funding

The work was supported by National Nature Science Foundation of China (81001103, 81472325), and Health, Science and Technology Chuang-Xin Talent Program of Henan Province, China (YXSC2021017).

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by Ethical Committee of the First Affiliated Hospital of Zhengzhou University (2022-KY-0134). Written informed consent was obtained from all patients before the procedures. All methods were performed in accordance with the guidelines and regulations of national/international/institutional and Declaration of Helsinki in the manuscript.

Consent for publication

Not applicable.

Competing interests

The authors declared that there were no conflicts of interest.

Author details

1 Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, No.1, East Jianshe Road, Zhengzhou 450052, China. 2 Department of Gastroenterology, Jiangsu Provincial Hospital, No.300, Guangzhou Road, Nanjing 210029, China. 3 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhenghou University, No.1, East Jianshe Road, Zhengzhou 450052, China.

Received: 1 July 2022 Accepted: 9 September 2022

Published online: 15 September 2022

References

1. Peery AF, Crockett SD, Murphy CC, Jensen ET, Kim HP, Egberg MD, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021. Gastroenterology. 2022;162(2):621–44.
2. Petrov MS, Yadav D. Global epidemiology and holistic prevention of pancreatitis. Nat Rev Gastroenterol Hepatol. 2019;16(3):175–84.
3. Kirkegård J, Gabel C, Lund J, Hinton SP, Ladelkai M, Heide-Jørgensen U, et al. Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis. Cancer Epidemiol. 2020;64:101647.
4. Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502.
5. Chen YH, Xie SM, Zhang H, Tan CL, Ke NW, Mai G, et al. Clinical impact of preoperative acute pancreatitis in patients who undergo pancreatoduodenectomy for periampullary tumors. World J Gastroenterol. 2015;21(22):6937–43.
6. Lankisch PG, Apte M, Banks PA. Acute pancreatitis. Lancet (London, England). 2015;386(9988):85–96.
7. Banks PA,ollen TL, Dervenis C, Goozen SH, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–11.
8. Sadri-Azodi O, Oskarsson V, Discacciati A, Viedeult P, Askling J, Ekbohm A. Pancreatic cancer following acute pancreatitis: a population-based matched cohort study. Am J Gastroenterol. 2018;113(1):1711–9.
9. Guda NM, Trikudanathan G, Freeman ML. Idiopathic recurrent acute pancreatitis. Lancet Gastroenterol Hepatol. 2018;3(10):720–8.
10. Kanchustambam S, Sharma A, Perkins Z, Patel A. Diagnostic performance of EUS in non-jaundiced patients with an incidental finding of double duct sign on cross-sectional imaging: a systematic review and meta-analysis. Pancreol. Off J Int Assoc Pancreatol (IAP). 2020;20(5):995–6.
11. Ruan Z, Jiao J, Min D, Ouy J, Li J, Chen J, et al. Multi-modality imaging features distinguish pancreatic carcinoma from mass-forming chronic pancreatitis of the pancreatic head. Oncol Lett. 2018;15(6):9735–44.
12. Del Vecchio BG, Gesualde V, Varanese M, Monteleone G, Paozzi OA. Idiopathic acute pancreatitis: a review on etiology and diagnostic work-up. Clin J Gastroenterol. 2019;12(6):511–24.
13. Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreol. Off J Int Assoc Pancreatol (IAP). 2020;20(5):795–800.
14. Öskarsson V, Hosseini S, Discacciati A, Viedeult P, Jans A, Ekbohm A, et al. Rising incidence of acute pancreatitis in Sweden: national estimates and trends between 1990 and 2013. United Eur Gastroenterol J. 2020;8(4):472–80.
15. Mujica VR, Barkin JS, Go VL. Acute pancreatitis secondary to pancreatic carcinoma. Study Group Particip Pac Pancreas. 2000;21(4):329–32.
16. Li S, Tian B. Acute pancreatitis in patients with pancreatic cancer: timing of surgery and survival duration. Medicine. 2017;96(3):e5908.
17. Minato Y, Kamisawa T, Tabata T, Hara S, Kuruma S, Chiba K, et al. Pancreatic cancer causing acute pancreatitis: a comparative study with cancer patients without pancreatitis and pancreas patients without cancer. J HepatobiliaryPancreat Sci. 2013;16(6):628–33.
18. Qiu X, Meng Y, Lu M, Tian C, Wang M, Zhang J. Primary squamous cell carcinoma of the pancreas with a large pseudocyst of the pancreas as the first manifestation: a rare case report and literature review. BMC Gastroenterol. 2021;21(1):208.
19. Federico E, Falconi M, Zuoar G, Falconieri G, Puglisi F. B-cell lymphoma presenting as acute pancreatitis. Pancreol. Off J Int Assoc Pancreatol (IAP). 2011;11(6):553–6.
20. Kwon TH, Park DH, Shim KY, Cho HD, Park JH, Lee SH, et al. Ampullary adenomyoma presenting as acute recurrent pancreatitis. World J Gastroenterol. 2007;13(20):2892–4.
21. Niccolini DG, Graham JH, Banks PA. Tumor-induced acute pancreatitis. Gastroenterology. 1976;71(1):142–5.
22. Fang Y, Kartsonaki C, Turnbull I, Guo Y, Yang L, Bian Z, et al. Metabolic and lifestyle risk factors for acute pancreatitis in Chinese adults: a prospective cohort study of 0.5 million people. PLoS Med. 2018;15(8):e1002618.
23. Xiong Y, Zhao Y, Han X, Chen G, Windsor J, Wu D, et al. Clinical characteristics and outcome of tumor-associated acute pancreatitis: a single-center cohort study. Ann Trans Med. 2021;9(8):639.
24. Saluja A, Maitra A. Pancreatitis and pancreatic cancer. Gastroenterology. 2019;156(7):1937–40.
25. Taskin OC, Adsay V. Lipase hypersecretion syndrome: a distinct form of paraneoplastic syndrome specific to pancreatic acinar carcinomas. Semin Diag Pathol. 2019;36(4):240–5.
26. Lippi G, Valentino M, Cervellin G. Laboratory diagnosis of acute pancreatitis: in search of the Holy Grail. Curr Rev Clin Lab Sci. 2012;49(1):18–31.
27. Kruger S, Haas M, Burger PJ, Ormanns S, Modest Df, Westphalen CB, et al. Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. J Cancer Res Clin Oncol. 2016;142(12):2585–91.
28. Tenner S, Baillie J, DeWitt J, Vege SS. American college of gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400–15.
29. Kothari S, Kalinowski M, Kozesko M, Almouradi T. Computed tomography scan imaging in diagnosing acute uncomplicated pancreatitis: usefulness vs cost. World J Gastroenterol. 2019;25(9):1080–7.
30. Zver T, Calame P, Koch S, Aubry S, Vuitton L, Delabrousse E. Early prediction of acute biliary pancreatitis using clinical and abdominal CT features. Radiology. 2022;302(1):118–26.
31. Cho JH, Choi JS, Hwang ET, Park JY, Jeon TJ, Kim HM, et al. Usefulness of scheduled follow-up CT in discharged patients with acute pancreatitis. Pancreol. Off J Int Assoc Pancreatol (IAP). 2015;15(S):642–6.
32. Parisi MA, Stevens T, Dumot JA, Zuccaro G Jr. Endoscopic therapy of recurrent acute pancreatitis. Clevel Clin J Med. 2009;76(4):225–33.
33. Marchegiani G, Andrianiello S, Morbin G, Secchettini E, D’Onofrio M, De Robertis R, et al. Importance of main pancreatic duct dilatation in IPMN undergoing surveillance. Br J Surg. 2018;105(13):1825–34.
34. Feng Q, Li C, Zhang S, Tan CL, Mai G, Liu XB, et al. Recurrence and survival after surgery for pancreatic cancer with or without acute pancreatitis. World J Gastroenterol. 2019;25(39):6006–15.
35. Singh V, Bolon TL, Wu BU, Repas K, Maurer R, Yu S, et al. An assessment of the severity of interstitial pancreatitis. Cln Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(12):1098–103.
36. Jachnis A, Slodkowski MT. The relationship between nutritional status and body composition with clinical parameters, tumor stage, CA19–9, CEA levels in patients with pancreatic and periampullary tumors. Current Oncol. 2021;28(6):4805–20.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.